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A B S T R A C T
In acute lymphoblastic leukemia (ALL), steroid resistance and hypovitaminosis D are both associated with a poor
prognosis. We show that methylprednisolone, calcitriol and the AKT-inhibitor MK-2206 have a synergistic eﬀect
on the apoptosis of steroid resistant T-ALL cells. Compared to methylprednisolone monotherapy, calcitriol in-
creases methylprednisolone induced apoptosis dose-dependently (1.37–1.92-fold; p < 0.05). Pre-incubation
with calcitriol increases the apoptotic eﬀect of MK-2206 even further (3.6-fold; p < 0.05). It also potentiates
synergism between MK-2206 and methylprednisolone (vehicle control 38% vs. calcitriol 58%, p < 0.01). The
combination of calcitriol and AKT inhibition should be investigated further as treatment options for steroid
resistance in T-ALL.
1. Introduction
Glucocorticoids (GC) are a core component of current treatment
protocols in T-cell acute lymphoblastic leukemia (T-ALL) and act
mainly through the induction of apoptosis [1]. Nevertheless, GC-re-
sistance is common in T-ALL, which negatively impacts the overall
prognosis [2,3]. In addition to GC-resistance, also hypovitaminosis D
appears to be associated with a decreased treatment response and a
reduced prognosis in patients with hematological malignancies [4].
More than 70% of children with ALL have subnormal levels of 1,25-OH2
vitamin D3 (calcitriol), which is the active form of vitamin D [5]. Using
primary human T-cells, we recently demonstrated that 1,25-OH2 vi-
tamin D3 upregulates the GC receptor and increases GC induced
apoptosis [6]. In this study, we aimed to investigate whether there is a
synergistic action of calcitriol on GC-induced apoptosis of a steroid
resistant T-ALL cell line (Jurkat). Since steroid resistance is also asso-
ciated with defective IL-7 signaling trough JAK/STAT, PI3K/AKT and
MEK [7], we furthermore investigated inhibitors of AKT (MK-2206),
JAK 1/2 (ruxolitinib) and MEK (CI-1040) for possible additional sy-
nergisms between GC and calcitriol.
2. Methods
Jurkat cells (Clone: E 6-1, kindly provided by the Department of
Virology, University of Bochum, Germany; 1×107 cells/ml) were cul-
tured in RPMI 1640 (Invitrogen, Carlsbad, USA), 1% penicillin/strep-
tomycin (Invitrogen), 300mg/l L-Glutamine (Invitrogen) with 10% FCS
(Sigma-Aldrich, St. Louis, USA) at stable ambient conditions (37 °C/5%
CO2). First, cells were treated with calcitriol (100 nM, 1 µM; Medchem
Express, Monmouth Junction, USA) dissolved in DMSO (ﬁnal DMSO
Table 1
Methylprednisolone induced apoptosis after 24 h of incubation.





MP 6.3 µM 6.3 (0.3) > 0.05
MP 63 µM 6.7 (0.3) > 0.05
MP .63mM 12.1 (0.8) < 0.05
MP 2.5mM 42.3 (5.0) < 0.05
MP 3.75mM 77.4 (2.9) < 0.05
Abbreviations: MP: Methylprednisolone, SEM: Standard Error of Mean.
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Fig. 1. Synergistic eﬀect between calcitriol and methylprednisolone on Jurkat apoptosis. A) Representative dot plot diagram of Jurkat cell apoptosis after 24 h
incubation with DMSO-control (a), 1 µM 1,25-OH2 vitamin D3 (b), 2.5 mM MP (c) and combination therapy (d). Annexin V/PI ﬂow cytometry staining. B) Percentage
of apoptotic Jurkat cells (Annexin V/PI) with 1.37 (VD 100 nM) to 1.92 (VD 1 µM) fold increase of MP-induced apoptosis compared to the untreated control. n= 5,
WSRT. MP: Methylprednisolone; SEM: standard error of the mean; WSRT: Wilcoxon Signed Rank Test.
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concentration in all conditions 0.25%), methylprednisolone (MP;
2.5 mM)/dexamethasone (800 µM, 1mM; Mibe, Brehna, Germany) or
the respective vehicle control for 24 h. Second, Jurkat cells were pre-
incubated with calcitriol (100 nM) or vehicle control for 24 h. Jurkat
cells were subsequently treated with the respective control, MP
(2.5 mM), ruxolitinib (2 µM, Selleckchem, Houston, USA)/ MK-2206
(2 µM, Selleckchem)/ CI-1040 (5 µM, Selleckchem), or a combination
(inhibitor + MP). After 24 h, apoptosis was evaluated by ﬂow cyto-
metry using Annexin V/PI staining (BD, San Jose, USA). All experi-
ments were repeated 5–10 times. Data are presented as mean and
standard error of the mean (SEM).
3. Results
We ﬁrst investigated whether calcitriol induces apoptosis in Jurkat
cells. Calcitriol treatment with up to 1 µM over 24 h did not induce
apoptosis in Jurkat cells (1 µM: 6.1% and 100 nM: 6.3% vs. control:
5.9%, each p > 0.05). In contrast, MP concentrations above 0.63mM
signiﬁcantly increased Jurkat cell apoptosis after 24 h (Table 1) com-
pared to the untreated control condition. To evaluate a possible sy-
nergism, Jurkat cells were co-incubated with MP (2.5mM) and calci-
triol (100 nM; 1 µM). This dual therapy resulted in a calcitriol dose-
dependent 1.37–1.92-fold increase of cell death (Fig. 1 A and B). This
eﬀect was not speciﬁc for MP since calcitriol also increased dex-
amethasone (800 µM, 1000 µM) induced apoptosis by 1.51–1.58 fold
synergistically with calcitriol (1 µM, p < 0.05; Supplementary Fig. 1).
Subsequently, we investigated whether the inhibition of signaling
pathways involved in steroid resistance in T-ALL and treatment with
MP/calcitriol have synergistic eﬀects on the induction of apoptosis.
Jurkat cells were pre-incubated with calcitriol (100 nM) or vehicle
control for 24 h. They were subsequently treated with the respective
control, MP, the MEK inhibitor CI-1040, the JAK 1/2 inhibitor rux-
olitinib and the AKT inhibitor MK-2206 or a combination thereof.
First, CI-1040 failed to demonstrate additional eﬀects on GC apop-
tosis irrespective of calcitriol supplementation (data not shown). In
contrast, the JAK 1/2 inhibitor ruxolitinib showed synergistic eﬀects
with MP. However, this eﬀect could not be increased by calcitriol pre-
incubation (Fig. 2A). The inhibition of the AKT signaling pathway using
MK-2206 also demonstrated a synergistic eﬀect with MP, which further
increased through calcitriol pre-incubation (Fig. 2B). Interestingly, also
a synergism between calcitriol and inhibition of the AKT pathway was
found, which exceeded synergistic eﬀects of MK-2206 and MP (Fig. 2B).
4. Discussion
In our study, we demonstrated that the observed synergism of calcitriol
and GC in primary human T-cells [6] can be transferred to a model of T-
ALL. This is an intriguing ﬁnding as it connects two important observations
in ALL patients: (I) a reduced overall prognosis of patients with a poor re-
sponse to steroids and (II) the deﬁciency of serum vitamin D3, especially of
serum 1,25-OH2 vitamin D3 [3,5]. We additionally investigated to what
extent calcitriol acts synergistically with the inhibitors of JAK 1/2, AKT and
MEK pathways, which are also relevant for steroid resistance in T-ALL [7].
We identiﬁed a synergistic action of calcitriol with the AKT inhibitor MK-
2206 alone as well as in combination with MP. Several vitamin D analogs
have already shown the ability to inhibit AKT. Therefore, the treatment with
MK-2206 and calcitriol could lead to a dual AKT inhibition, which might
explain our ﬁnding [8]. The presented study bears several weaknesses and
should only be interpreted as a pilot investigation. 1,25-OH2D3/MP con-
centrations used in our in vitro analysis are higher than achieved in ther-
apeutic situations. Additionally, conﬂicting evidence exists concerning the
eﬀects of 1,25-OH2 vitamin D3 on dexamethasone eﬃcacy in several pre-B
ALL cell lines [9]. Nevertheless, our study clearly argues for additional re-
search to investigate the eﬀect of calcitriol on the therapeutic eﬃcacy of
glucocorticoids and AKT-inhibition in T-ALL patients and might have clin-
ical implications for steroid resistant T-ALL.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.lrr.2018.01.003.
Fig. 2. Ruxolitinib's and MK-2206 synergism with methylprednisolone and the eﬀect of additional vitamin D supplementation. A) Ruxolitinib increases MP-induced
apoptosis after 24 h pre-incubation with calcitriol (19% increase, p < 0.05) or vehicle control (91% increase, p < 0.01); n= 10, WSRT. B) AKT inhibition through
MK-2206 treatment increases MP-induced apoptosis after pre-incubation with calcitriol (58%; p < 0.05) or vehicle control for 24 h (38%; p > 0.05); n=5, WSRT.
Abbreviations: MP: methylprednisolone; SEM: standard error of the mean. WSRT: Wilcoxon Signed Rank Test.
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